Novo Nordisk A/S (NYSE:NVO) Shares Sold by Lindbrook Capital LLC

Lindbrook Capital LLC decreased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 1.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,887 shares of the company’s stock after selling 180 shares during the quarter. Lindbrook Capital LLC’s holdings in Novo Nordisk A/S were worth $1,023,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of NVO. Roundview Capital LLC boosted its position in shares of Novo Nordisk A/S by 0.6% during the 1st quarter. Roundview Capital LLC now owns 18,803 shares of the company’s stock valued at $2,088,000 after acquiring an additional 106 shares during the last quarter. BlackRock Inc. raised its holdings in Novo Nordisk A/S by 45.4% in the 1st quarter. BlackRock Inc. now owns 5,035,879 shares of the company’s stock valued at $559,235,000 after buying an additional 1,571,747 shares during the period. Dimensional Fund Advisors LP raised its holdings in Novo Nordisk A/S by 0.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 739,585 shares of the company’s stock valued at $82,131,000 after buying an additional 6,903 shares during the period. Blair William & Co. IL raised its holdings in Novo Nordisk A/S by 12.7% in the 1st quarter. Blair William & Co. IL now owns 19,466 shares of the company’s stock valued at $2,136,000 after buying an additional 2,194 shares during the period. Finally, Sei Investments Co. raised its holdings in Novo Nordisk A/S by 17.5% in the 1st quarter. Sei Investments Co. now owns 107,175 shares of the company’s stock valued at $11,913,000 after buying an additional 15,996 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 0.0 %

Novo Nordisk A/S stock traded down $0.04 during mid-day trading on Friday, hitting $122.71. The company had a trading volume of 5,183,469 shares, compared to its average volume of 3,262,533. The stock has a market cap of $550.66 billion, a price-to-earnings ratio of 45.36, a PEG ratio of 2.05 and a beta of 0.41. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $138.28. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. The business has a fifty day moving average of $126.39 and a 200 day moving average of $110.88.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.66 by $0.05. The company had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. On average, sell-side analysts expect that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were paid a $0.664 dividend. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a yield of 0.9%. The ex-dividend date of this dividend was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio is currently 49.17%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective on the stock. UBS Group assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating on the stock. BMO Capital Markets assumed coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 price target on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.